Erin Allman‑Updyke and Erin Welsh
speaker
988 appearances
1 recordings
1 series
first heard Aug 2026
last heard 4 Aug
Erin Allman‑Updyke and Erin Welsh’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 1 in all, peaking in Aug 2026 with 1.
Appearances
So we talked about that meta analysis from 10 years ago or so.
PCSK9 inhibitors reduce your LDL drastically.
and can drastically also reduce cardiovascular events, especially in people who are very high risk, meaning people that we are doing secondary prevention, who already have cardiovascular disease, who have maybe already had a heart attack or a stroke, and we really need to lower that cholesterol, or people who are just very high risk, right?
So in those populations is mostly where it's been studied.
And so cardiologists love this medicine.
The biggest issues are, as with all new drugs, especially ones that are fancy things like siRNA and monoclonal antibodies, they are expensive as heck, especially in this country.
We also just don't have nearly as much data on them as we do for statins.
So the error bars on their benefit is still messier, even though they still have a really good effect.
Do we have information about side effects of statins?
That's a great question.
I should have looked into it more.
There definitely can be side effects, but I honestly just did not do a good job of looking into them as much.
So I will get back to you on that.
Okay.
And then I have a question sort of like about lowering.
So we've talked about lowering and the importance of having lower levels, but there is such a thing as too low.
What are consequences of that?
That's a great question.
I don't have a number for you.
What the data shows is that the higher your individual risk of cardiovascular disease, right?
Showing 781–800 of 988 · page 40 of 50
← Previous
Next →